InspireMD reports updated CGuard EPS data at VEITH 2019
InspireMD reported on updated registry study data presented at the 2019 VEITH Symposium, which was held November 19-23 in New York City. Summary of the presentations are as follows: Title: Preliminary Results from a Prospective Real World Multicenter Clinical Practice of Carotid Artery Stenting Using the CGuard Embolic Prevention System: The IRONGUARD 2 Study. Highlights: Procedural success was achieved in 100% of patients; At 24 hours post-procedure, the complication rate was 0.73%; Data from 529 patients at one-month follow-up showed a stroke complication rate of 0.54%. The accumulated neurologic event rate at 30 days was 1.63%; Data from 253 patients at one-year follow-up showed no further neurologic events. Conclusion: Data from this study suggests that the use of CGuard EPS in routine clinical practice is associated with no major periprocedural, 30-day or one-year neurological complications. Title: Update on the C-Guard MicroNet Mesh Covered Stent for CAS: Longer Term Results: Advantages and Are There Late Downsides Like ISR or Late Thrombosis. Highlights: The PARADIGM-Extend study enrolled 402 patients, all of whom were treated using CGuard EPS; Peri-procedural outcome included one minor stroke and one type 2 myocardial infarction, yielding a neurological event rate of 0.5%; There were no deaths or major strokes; At 30 days follow-up, the neurological event rate was 0.5%, including one hemorrhagic transformation of prior ischemic cerebral infarct leading to death and one bleeding-related death; The 30-day accumulated neurological event rate was 1.0%; There were no reported post procedural ischemic strokes; Patient follow-up data at 12, 24, 36 and 48 months suggest that CGuard EPS continues to maintain a favorable safety profile. CONCLUSION: Long-term patient follow-up out to 48 months show that CGuard EPS maintains a long-term clinical benefit.